Who owns Denali Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of DNLI from SEC Form 13F filings across 287 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 287 institutions disclosed 152.4M shares of Denali Therapeutics Inc. worth $3.15B — about 80.9% of shares outstanding; the largest disclosed holder is T. Rowe Price Investment Management, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
287
13F holders
$3.15B
value, 2026 filers
80.9%
of shares outstanding (152.4M sh)
39
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of DNLI's shares outstanding
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.